+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Molecular determinants of retinoic acid sensitivity in pancreatic cancer.

      Clinical cancer research : an official journal of the American Association for Cancer Research

      Animals, Antineoplastic Agents, pharmacology, Apoptosis, drug effects, Blotting, Western, Carcinoma, Pancreatic Ductal, drug therapy, genetics, metabolism, Cell Adhesion, Cell Movement, Cell Proliferation, DNA Methylation, Fatty Acid-Binding Proteins, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Immunoenzyme Techniques, Mice, Mice, Nude, Oligonucleotide Array Sequence Analysis, Pancreatic Neoplasms, Promoter Regions, Genetic, RNA, Messenger, Real-Time Polymerase Chain Reaction, Receptors, Retinoic Acid, Tretinoin, Tumor Cells, Cultured, Tumor Markers, Biological

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          To identify a predictive molecular "signature" for sensitivity to retinoic acid in pancreatic cancer. Fourteen patient-derived, low-passage pancreatic ductal adenocarcinoma (PDAC) lines with varied expression of fatty acid-binding protein 5 (FABP5) and cellular retinoic acid-binding protein 2 (CRABP2) were used to evaluate the response to all-trans retinoic acid (ATRA). Cell proliferation, apoptosis, and migration/invasion assays were used to measure the in vitro response. Tumor growth was monitored in subcutaneous xenografts in athymic nude mice for 4 weeks. Response to ATRA was observed to be dependent upon differential expression of FABP5 versus CRABP2. Thus, elevated FABP5 expression was associated with minimal cytotoxicity and tumor growth inhibition and a paradoxical increase in migration and invasion. Conversely, CRABP2 expression in the absence of FABP5 was associated with significant tumor growth inhibition with ATRA, even in gemcitabine-resistant tumors. The ATRA-resistant phenotype of FABP5(high)CRABP2(null) cells could be circumvented by ectopic expression of CRABP2. Alternatively, reexpression of endogenous CRABP2 could be enabled in FABP5(high)CRABP2(null) PDAC lines by exposure to decitabine and trichostatin A, thereby relieving epigenetic silencing of the CRABP2 gene promoter. Immunohistochemical staining for FABP5 in archival human tissue microarrays identifies a subset of cases (13 of 63, ~20%) which are negative for FABP5 expression and might be candidates for ATRA therapy. The widely used agent ATRA deserves a "second look" in PDAC, but needs to be targeted to patient subsets with biopsy-proven FABP5-negative tumors, or be combined with a chromatin-modifying agent to reexpress endogenous CRABP2. © 2011 AACR.

          Related collections

          Author and article information



          Comment on this article